News Archive
Resources Section
Contact
UK Office
Only Medics
Second Floor
7 - 11 Station Road
Reading, Berkshire
RG1 1LG, UK
Tel -
+44(0)1189 522799
Email -
info@onlymedics.com
EU Office
Only Medics
Quantum House
22 - 24 Red Lion Court
Fleet Street, London
EC4A 3EB, UK
Tel -
+44(0)2078 221719
Share &
Connect
Keep connected & join the Only Medics Network here.
Specialist Sectors
-
Mobile – the device powering the next big evolution of human health behavior
Continuing our mHealth theme this month, Leigh Householder investigates how mobile is changing human behaviour, particularly with regards to health. Maybe you've had this debate: Is mobile a device, ...
-
GSK buys more of Theravance
GlaxoSmithKline now owns more than a quarter of biopharma company Theravance after shelling out nearly $213 million to buy ten million extra shares. GSK has upped its stake significantly from 18...
-
OPEN Health invests in Harvey Walsh
Harvey Walsh, a market access and healthcare intelligence company, is to join forces with OPEN Health, the healthcare communications group. OPEN Health has taken a 51% stake in Harvey ...
-
The ageing population – the need for pharma to be disruptive in addressing the needs of senior consumers
Following our mobile health theme, Dr. Michael Reilly shares his views on how pharma needs to address the ageing population. This article calls for new, disruptive and radical approaches by Pharma t...
-
Giving statins to the well saves lives, research finds
Giving statins to the well saves lives, research finds...
-
Teva re-elects Chairman of the Board
Teva has announced that its Board of Directors has unanimously voted to re-elect Dr Phillip Frost as Chairman of the Board for a term of three years. Frost’s re-election as a director is subje...
-
Plavix loses US patent protection
Sanofi and Bristol-Myers Squibb’s blood thinner Plavix has lost its patent protection in the US. The drug, which made $6.6 billion in US sales last year, will now compete with generic copies f...
-
HGS adopts poison pill to thwart GSK, in talks with other firms
HGS adopts poison pill to thwart GSK, in talks with other firms...
-
FDA opens gates for generic Plavix as patent expires
FDA opens gates for generic Plavix as patent expires...
-
US FDA reviews new drugs faster than EMA, Health Canada, says study
US FDA reviews new drugs faster than EMA, Health Canada, says study...
-
NICE to be sidelined on cost effectiveness - once again
Health secretary Andrew Lansley has confirmed that NICE will no longer direct the NHS on the cost effectiveness of drugs. His remarks made at the NICE conference in Birmingham yesterday come as a surp...
-
Tunnah’s musings: is being app-ey the key to good health?
Mobile health themed musings from Paul Tunnah this month, as he ponders whether the world of pharma drugs and mhealth apps might not be so different. It may have escaped your notice so far but we’v...
-
New Novartis COPD drug beats placebo over a year
New Novartis COPD drug beats placebo over a year...
-
NICE comes out fighting against appraisal delays story
NICE has criticised a report that says the watchdog has taken up to nine years to appraise certain drugs. The report by the Office of Health Economics, which was commissioned by Pfizer, sa...
-
Tolerability of Aveo/Astellas kidney cancer drug impresses
Tolerability of Aveo/Astellas kidney cancer drug impresses...
-
Has the push for transparency gone too far? (Part 1)
Darshan Kulkarni asks if the push for transparency, as initiated by the Sunshine Act in the US, has gone too far. There has been a recent surge in requests for disclosures of relationships between in...
-
India's Piramal buys data provider Decision Resources
India's Piramal buys data provider Decision Resources...
-
Pfizer's Xalkori shows promise in rare childhood cancers
Pfizer's Xalkori shows promise in rare childhood cancers...
-
Medivir appoints commercial executive vice president
Research-based speciality firm Medivir has appointed Henric Juserius to be the new head of the company's commercial activities. Juserius who will have overall responsibility for Medivir’s phar...
-
GSK pays $213 million to raise stake in Theravance to 26.7%
GSK pays $213 million to raise stake in Theravance to 26.7%...
News
- May 18, 2012 Mobile – the device powering the next big evolution of human health behavior
- May 18, 2012 GSK buys more of Theravance
- May 18, 2012 OPEN Health invests in Harvey Walsh
- May 18, 2012 The ageing population – the need for pharma to be disruptive in addressing the needs of senior consumers
- May 18, 2012 Giving statins to the well saves lives, research finds
Testimonials
- Right from the very start, I have been p...
- Exceptional service demands recognition....
- Thank you for all your help and support ...
- I want to thank you for your help and gu...
- Thank you for all your help and support ...
- Thanks so much for helping me to find a ...
- As of today I have been in-post for 3 mo...
- Thanks so much for your help and negotia...
- We had been trying to recruit for two me...
- I just wanted to put in writing my grati...